Attached files

file filename
10-Q - QUARTERLY REPORT - Pathfinder Cell Therapy, Inc.f10q0315_pathfinder.htm
EX-31.1 - CERTIFICATION - Pathfinder Cell Therapy, Inc.f10q0315ex31i_path.htm
EX-32.1 - CERTIFICATION - Pathfinder Cell Therapy, Inc.f10q0315ex32i_path.htm
EX-31.2 - CERTIFICATION - Pathfinder Cell Therapy, Inc.f10q0315ex32ii_path.htm
EX-31.2 - CERTIFICATION - Pathfinder Cell Therapy, Inc.f10q0315ex31ii_path.htm
EXCEL - IDEA: XBRL DOCUMENT - Pathfinder Cell Therapy, Inc.Financial_Report.xls

Exhibit 10.1

 

CONVERTIBLE PROMISSORY NOTE

 

$__________      Cambridge, Massachusetts
    Date: ___________

 

For value received, the undersigned, Pathfinder Cell Therapy, Inc., a Delaware corporation (the “ Borrower ”), hereby unconditionally promises to pay to the order of _____________ (the “ Payee ”), the principal sum of $_______   and 00/100   Dollars ($_________ ), together with interest to maturity (whether by lapse of time, acceleration or otherwise) on the balance of principal remaining from time to time outstanding at a rate per annum equal to 6%. Interest shall be calculated on the basis of a 360-day year and actual days.

 

The outstanding principal amount, together with accrued interest, of this Promissory Note shall become due and payable on the first anniversary of the date hereof.

 

Payee may elect, at any time prior to completion or termination of the Capital Raise (defined below), upon written notice to Borrower, to convert all or a portion of the outstanding principal and/or interest hereof, to shares of common stock of the Borrower, for the subscription price thereof, in the Capital Raise.  “Capital Raise” has the meaning used in that certain agreement and plan of merger dated December 22, 2010 (as amended) by and among Borrower, a wholly-owned subsidiary of Borrower, and Pathfinder, LLC, a Massachusetts limited liability company, pursuant to which Borrower acquired Pathfinder, LLC in a merger transaction, the initial closing of which Capital Raise occurred in September 2011 immediately after the merger. As a condition to any such conversion, Payee shall execute and deliver to Borrower such agreements and documentation as Borrower requires of other investors in the Capital Raise.

 

The Borrower shall have the right to prepay, at any time, all or any portion of the principal indebtedness evidenced by this Note, together with any accrued interest.

 

No failure by the holder of this Note to exercise, and no delay in exercising, any right or power hereunder shall operate as a waiver thereof, nor shall any single or partial exercise by such holder of any right or power preclude any other or further exercise thereof or the exercise of any other right or power.  The rights and remedies of the holder hereof as herein specified are cumulative and not exclusive of any other rights or remedies which such holder may otherwise have.

 

The undersigned agrees to pay all costs and expenses incurred by the holder hereof in enforcing this Note, including, without limitation, reasonable attorneys’ fees and disbursements.

 

1
 

 

Every maker, endorser and guarantor of this Note hereby waives presentment, demand and protest, and consents to any and all extensions and other indulgences granted by the holder hereof and agrees that no such extensions or other indulgences granted by the holder, and no discharge or release of any other party primarily or secondarily liable on this Note, or of any collateral securing this Note, shall operate to discharge the indebtedness evidenced by this Note.  If this Note is signed by more than one person, all references to the Borrower shall apply to each of them and their liabilities hereunder shall be joint and several.

 

Any notice of non-payment shall be deemed given when delivered in hand or when mailed, postage prepaid, by certified or registered mail, return receipt requested to the Borrower at 12 Bow Street, Cambridge, Massachusetts 02138 or sent thereto by Federal Express or comparable overnight courier.

 

This Note shall be governed and construed in accordance with the laws of the State of New York applicable to contracts made and to be performed therein (excluding choice of law principles).

 

IN WITNESS WHEREOF, the undersigned has executed or caused this Note to be executed under seal as of the year and day first written above.

 

WITNESS    PATHFINDER CELL THERAPY, INC.
       
    By:  
      Richard L. Franklin, CEO

 

2
 

 

Schedule of Promissory Notes
        
Date of issuance  Note Holder  Principal amount 
        
February 2, 2012  Falcon Corporate Investments Limited  $150,000 
         
February 29, 2012  Falcon Corporate Investments Limited  $170,000 
         
March 15, 2012  Falcon Corporate Investments Limited  $250,000 
         
April 23, 2012  Falcon Corporate Investments Limited  $150,000 
         
May 25, 2012  Skye Asset Management SA  $270,000 
         
June 20, 2012  Ventura, Inc.  $225,000 
         
July 27, 2012  Ventura, Inc.  $50,000 
         
August 17, 2012  Breisgau Bio Ventures SA  $100,000 
         
October 1, 2012  Breisgau Bio Ventures SA  $200,000 
         
October 23, 2012  Breisgau Bio Ventures SA  $200,000 
         
November 20, 2012  Breisgau Bio Ventures SA  $70,000 
         
December 4, 2012  Breisgau Bio Ventures SA  $70,000 
         
December 21, 2012  Breisgau Bio Ventures SA  $60,000 
         
January 9, 2013  Breisgau Bio Ventures SA  $75,000 
         
January 28, 2013  Breisgau Bio Ventures SA  $130,000 
         
March 4, 2013  Mr. Joerg Gruber  $100,000 
         
April 2, 2013  Ventura, Inc.  $150,000 
         
April 29, 2013  Ventura, Inc.  $150,000 
         
 May 28, 2013  Breisgau Bio Ventures SA  $250,000 
         
June 26, 2013  Breisgau Bio Ventures SA  $150,000 

 

3
 

         
July 24, 2013  Breisgau Bio Ventures SA  $170,000 
         
August 24, 2013  Breisgau Bio Ventures SA  $100,000 
         
September 26, 2013  Breisgau Bio Ventures SA  $100,000 
         
October 22, 2013  Breisgau Bio Ventures SA  $135,000 
         
November 22, 2013  Breisgau Bio Ventures SA  $100,000 
         
December 20, 2013  Breisgau Bio Ventures SA  $125,000 
         
January 21, 2014  Breisgau Bio Ventures SA  $105,000 
         
February 24, 2014  Breisgau Bio Ventures SA  $120,000 
         
March 25, 2014  Breisgau Bio Ventures SA  $105,000 
         
April 24, 2014  Ventura, Inc.  $100,000 
         
May 28, 2014  Ventura, Inc.  $120,000 
         
June 5, 2014  Ventura, Inc.  $30,000 
         
June 26, 2014  Ventura, Inc.  $50,000 
         
August 5, 2014  Ventura, Inc.  $50,000 
         
August 21, 2014  Ventura, Inc.  $100,000 
         
September 25, 2014  Ventura, Inc.  $80,000 
         
October 24, 2014  Ventura, Inc.  $35,000 
         
November 28, 2014  Ventura, Inc.  $60,000 
         
December 30, 2014  Ventura, Inc.  $50,000 
         
February 2, 2015  Ventura, Inc.  $75,000 
         
March 5, 2015  Ventura, Inc.  $55,000 
         
March 27, 2015  Breisgau Bio Ventures SA  $55,000 
         
May 11, 2015  Breisgau Bio Ventures SA  $50,000 
         
   Aggregate Principal amount  $4,940,000 

 

 

4